Liposome nano-particles with ROS response as well as preparation method and application of liposome nano-particles
Through the preparation of ROS-responsive liposome nanoparticles, combining hemoglobin and targeted peptides, nanoparticles that can cross the blood-brain barrier are formed, solving the problem that existing drugs are difficult to cross the blood-brain barrier, and significantly improving the efficiency and supply of brain delivery Oxygen efficiency provides an efficient drug delivery system for the treatment of stroke.
Patent Information
- Application Number
- CN202411005223.7
- Authority / Receiving Office
- CN · China
- Patent Type
- Applications(China)
- Current Assignee / Owner
- Filing Date
- 2024-07-25
- Publication Date
- 2024-11-08
AI Technical Summary
Existing drugs for treating stroke are difficult to cross the blood-brain barrier, resulting in limited efficacy and low targeting efficiency. The targeting efficiency of existing nanocarriers in stroke tissues also needs to be improved.
Using the preparation method of ROS-responsive liposome nanoparticles, MLT@Hb nanoparticles are synthesized, and MG1 is connected to SMCC, combined with DSPE-TK-PEG2000-RVG29, forming microglia that can target microglia and pass through the blood-brain barrier. MLT@Hb-MLR nanoparticles realize a secondary targeted delivery system.
It significantly improves the brain delivery efficiency and oxygen supply efficiency of drugs, can pass through the blood-brain barrier, target blocked areas in the brain, improves the inflammatory environment, and provides a more efficient drug delivery system for the treatment of stroke.
Smart Images

Figure CN118903460A_ABST
Abstract
Description
Technical Field
[0001] The present invention relates to the technical field of nanomedicine, in particular to IPC A61K47, and more specifically to ROS-responsive liposome nanoparticles and a preparation method and application thereof. Background Art
[0002] Stroke, also known as infarction, includes ischemic stroke and hemorrhagic stroke. It refers to a group of organic cerebrovascular diseases caused by stenosis or occlusion of blood vessels and rupture of blood vessels in the brain. Its main clinical features are sudden onset and rapid onset of neurological dysfunction. In recent years, with the acceleration of the aging process of the social population and the change in the living structure of residents, the global stroke disease has generally shown a trend of high incidence, high disability rate, high mortality rate, high recurrence rate and many complications. There is no doubt that stroke is seriously threatening the physical and mental health of residents around the world.
[0003] Despite advances in modern medicine, drug development for the treatment of stroke remains challenging. Compared to most other areas of drug discovery, the failure rate of new drugs for major stroke is high. There are currently a variety of treatments, including surgery, deep brain stimulation, intravenous (IV), oral and topical dosage forms, and rehabilitation therapy. However, traditional therapies have certain limitations. Due to the existence of the blood-brain barrier, only a small amount of drugs reaches the brain and the efficacy is limited. In contrast, short-term and highly invasive surgical methods and brain implants are considered unsafe treatments. Therefore, the development of drugs with the ability to cross the blood-brain barrier and enter the brain for the treatment of stroke has great prospects.
[0004] The existing patent CN202310662773.5 discloses a method for preparing a polyfingolimod nanoprodrug coated with a neutrophil membrane, and designs a polymer prodrug nanocarrier composed of a fingolimod polymer "core" and a neutrophil membrane "shell" that responds to reactive oxygen in the microenvironment of stroke tissues for specific delivery of fingolimod to counteract the damage of local inflammation of ischemic stroke to the nervous system. However, its targeting efficiency needs to be improved. Summary of the invention
[0005] In order to solve the problems in the prior art, the first aspect of the present invention provides a method for preparing liposome nanoparticles with ROS response and secondary targeting functions, comprising the following steps: synthesizing MLT@Hb nanoparticles, and then accessing MG1 through SMCC (4-(N-maleimidomethyl)cyclohexane-1-carboxylic acid succinimide ester) to form MLT@Hb-MG1; preparing DSPE-TK-PEG2000-Mal and RVG29 to form DSPE-TK-PEG2000-RVG29, and then mixing DSPE-TK-PEG2000-RVG29, MLT@Hb-MG1, soybean phosphatidylcholine, and cholesterol to form ROS-responsive liposome nanoparticles.
[0006] Preferably, the method for preparing the ROS-responsive liposome nanoparticles comprises the following specific steps:
[0007] S1: Synthesis of MLT@Hb nanoparticles: Hb (hemoglobin) and melatonin solution were mixed in a buffer solution and stirred at room temperature for 3 to 6 hours. After completion, the excess free substances were removed by dialysis to obtain MLT@Hb nanoparticles.
[0008] S2: Synthesis of MLT@Hb-MG1: MLT@Hb nanoparticles and SMCC were mixed, pH was adjusted, stirred at room temperature for 45-60 min, MG1 targeting peptide was added, reacted for 10-15 h, and purified by dialysis to obtain MLT@Hb-MG1;
[0009] S3: Synthesis of DSPE-TK-PEG2000-RVG29: DSPE-TK-PEG2000-Mal and RVG29 cell targeting peptide were dissolved in PBS, stirred at room temperature overnight, and dialyzed to remove free RVG29 cell targeting peptide to obtain DSPE-TK-PEG2000-RVG29;
[0010] S4: MLT@Hb-MLR synthesis:
[0011] (1) Weighing hydrogenated soybean phosphatidylcholine, cholesterol and DSPE-TK-PEG2000-RVG29, dissolving them in a solvent and heating to dissolve them, to obtain an oil phase;
[0012] (2) adding the mixed solution to a solvent to obtain an oil phase;
[0013] (3) dissolving MLT@Hb-MG1 in water to prepare an aqueous solution to obtain an aqueous phase;
[0014] (4) The oil phase is added dropwise into the aqueous phase to obtain colostrum, and the particle size of MLT@Hb-MLR is regulated by a liposome extruder. After dialysis and ultrafiltration, hemoglobin nanoparticles MLT@Hb-MLR are obtained.
[0015] Preferably, the raw materials prepared in step S1 further include one or more of dopamine hydrochloride, BSA (bovine serum albumin), HAS (human serum albumin), and pigment protein.
[0016] Preferably, the mass ratio of Hb to melatonin in the melatonin solution is (3-7):2; more preferably, it is 5:2.
[0017] Preferably, the melatonin solution is a melatonin ethanol solution; the mass volume ratio of melatonin to ethanol is 1:(90-110); further preferably, it is 1:100.
[0018] Preferably, the filter membrane specifications used in S1 are 0.22 μm, 0.45 μm, 0.8-1.0 μm and 1-5 μm; further, 0.22 μm.
[0019] Preferably, the dialysis time in S1 is 22 to 30 hours, and more preferably, it is 24 hours.
[0020] Preferably, the molar ratio of MLT@Hb nanoparticles to SMCC in S2 is (1-3):1; more preferably, it is 1:1.
[0021] Preferably, the pH of S2 is 7.0 to 7.5; more preferably, it is 7.2.
[0022] Preferably, the molar ratio of SMCC to MG1 targeting peptide is (1-3):1; more preferably, it is 1:1.
[0023] Preferably, the mass ratio of DSPE-TK-PEG2000-Mal and RVG29 cell targeting peptide in S3 is (1-3):1; further preferably, it is 1:1.
[0024] Preferably, the pH of the PBS in S3 is 7.2-7.4.
[0025] Preferably, the mass ratio of hydrogenated soybean phosphatidylcholine, cholesterol and DSPE-TK-PEG2000-RVG29 in S4 is (2-4):(1-2):1; more preferably, it is 3:1:1.
[0026] Preferably, the solvent in S4 is anhydrous ethanol.
[0027] Preferably, the volume ratio of the mixed solution to the solvent in S4(2) is 1:(2-5); more preferably, it is 1:3.
[0028] Preferably, the concentration of the aqueous solution in S4(3) is 0.5-1.5 mg / mL; more preferably, it is 1 mg / mL.
[0029] Preferably, the volume ratio of the oil phase to the water phase in S4(4) is 4:(20-30); more preferably, it is 4:25.
[0030] In the present invention, melatonin (MLT) and MG1 are loaded on Hb to improve the brain inflammation environment. The inventors found that MG1 can target microglia, Hb hemoglobin has good biocompatibility, MLT has a certain therapeutic inflammatory environment, Hb, MLT and MG1 and natural infarction area targeting, and can achieve binding-release of oxygen, supply oxygen to the infarction area, and improve oxygen supply efficiency.
[0031] In the present invention, the brain delivery efficiency is improved by using a cell targeting peptide RVG29 composed of 29 amino acids. The inventors found that the RVG29 cell targeting peptide has a strong affinity with cerebral vascular endothelial cells, can pass through the blood-brain barrier, enter the blocked part of the brain, and can significantly improve the brain delivery efficiency.
[0032] The second aspect of the present invention provides a method for preparing liposome nanoparticles, and the liposome nanoparticles prepared are MLT@Hb-MLR.
[0033] The third aspect of the present invention provides an application of liposome nanoparticles for preparing a drug for treating stroke.
[0034] Beneficial Effects
[0035] 1. In the present invention, melatonin (MLT) is loaded onto specific hemoglobin Hb to form small-diameter nanoparticles (30-40 nm), and MG1 targeting peptide is externally connected to form MLT@Hb-MG1. Then, liposomes with ROS-responsive components are used to encapsulate the MLT@Hb-MG1 particles, and RVG-29 targeting peptide is externally connected to form a secondary targeted nanodrug delivery system for the treatment of stroke, which provides strong support for the treatment of stroke.
[0036] 2. In the present invention, the brain delivery efficiency is improved by the cell targeting peptide RVG29 composed of 29 amino acids. The inventors found that the RVG29 cell targeting peptide has a strong affinity with cerebral vascular endothelial cells, can pass through the blood-brain barrier, enter the blocked part of the brain, and significantly improve the brain delivery efficiency.
[0037] 3. In the present invention, melatonin MLT and MG1 are loaded by Hb to improve the brain inflammation environment. The inventors found that MG1 can target microglia, Hb hemoglobin has good biocompatibility, MLT has a certain therapeutic inflammatory environment, Hb, MLT and MG1 and natural infarction area targeting, and can achieve binding-release oxygen, supply oxygen to the infarction area, and improve oxygen supply efficiency.
[0038] 4. In the present invention, a specific DSPE-TK-PEG2000-Mal is selected, which can not only connect to the RVG-29 targeting peptide, but also improve the ROS responsiveness.
[0039] 5. In the present invention, a secondary targeted liposome nanodrug delivery system with ROS response and secondary targeting is formed through a specific combination of specific Hb, dopamine hydrochloride, SMCC, MG1 targeting peptide, DSPE-PEG2000-Mal, and RVG29. BRIEF DESCRIPTION OF THE DRAWINGS
[0040] Figure 1 Schematic diagram of the structure of the liposome nanoparticle MLT@Hb-MLR in Example 1;
[0041] Figure 2 The left figure is a UV-visible absorption spectrum of the liposome nanoparticle MLT@Hb-MLR during the synthesis process in Example 1; the left figure is a UV-visible absorption spectrum of the MLT@Hb during the synthesis process; the right figure is a UV-visible absorption spectrum of the DSPE-TK-PEG2000-RVG29 during the synthesis process;
[0042] Figure 3 The infrared spectrum of the hemoglobin nanoparticles MLT@Hb-MLR during the synthesis process in Example 1; the upper left is the infrared spectrum of the MLT@Hb nanoparticles during the synthesis process; the lower left is the infrared spectrum of the MLT@Hb-MG1 during the synthesis process; the upper right is the infrared spectrum of the DSPE-PEG2000-RVG29 during the synthesis process; the lower right is the infrared spectrum of the MLT@Hb-MLR during the synthesis process;
[0043] Figure 4 The particle size distribution diagram of MLT@Hb, MLT@Hb-MG1, and MLT@Hb-MLR in Example 1;
[0044] Figure 5 : is the potential distribution diagram of MLT@Hb, MLT@Hb-MG1, and MLT@Hb-MLR in Example 1;
[0045] Figure 6 This is a stability curve diagram of measuring MLT@Hb-MLR in Example 1;
[0046] Figure 7 TEM morphology images of Hb, MLT@Hb, MLT@Hb-MG1, and MLT@Hb-MLR in Example 1;
[0047] Figure 8 The changes in particle size and PDI of the responsive nanoparticles of MLT@Hb-MLR at different time points in Example 1, as well as the TEM image at 24 hours.
[0048] Fig. 9 Figure 2 shows the responsive release diagram of MLT@Hb-MLR under different H2O2 concentrations. DETAILED DESCRIPTION
[0049] Example 1
[0050] The first aspect of the present invention provides a method for preparing liposome nanoparticles with ROS response and secondary targeting functions, comprising the following specific steps:
[0051] S1: Synthesis of MLT@Hb nanoparticles: Hb (hemoglobin) (5.0 mg), dopamine hydrochloride (PDA) (6.0 mg), and melatonin solution (2 mg, dissolved in 200 μL ethanol) were mixed in 6 mL 10 mM Tris buffer (pH 8.5), stirred at 25 °C for 3 h, and then dialyzed for 24 h to remove excess free dopamine hydrochloride, and filtered with a 0.22 μm filter membrane to obtain MLT@Hb nanoparticles;
[0052] S2: Synthesis of MLT@Hb-MG1: MLT@Hb nanoparticles and cysteine (SMCC) were mixed in a molar ratio of 1:1, the pH was adjusted to 7.2, stirred at 25 °C for 45 min, and then the MG1 targeting peptide with the same molar amount as cysteine was added, reacted for 12 h, and purified by dialysis to obtain MLT@Hb-MG1;
[0053] S3: Synthesis of DSPE-TK-PEG2000-RVG29: DSPE-TK-PEG2000-Mal (3 mg) and RVG29 cell targeting peptide (3 mg) were dissolved in 2 mL PBS (pH 7.3), stirred at 25°C overnight, and dialyzed to remove free RVG29 cell targeting peptide to obtain DSPE-TK-PEG2000-RVG29;
[0054] S4: MLT@Hb-MLR synthesis:
[0055] (1) Weigh hydrogenated soybean phosphatidylcholine HSPC (30 mg), cholesterol (10 mg) and DSPE-TK-PEG2000-RVG29 (10 mg), dissolve them in 1 mL of ethanol, and heat to 40° C. to obtain a mixed solution;
[0056] (2) adding 200 μL of the mixed solution to 600 μL of ethanol to obtain an oil phase;
[0057] (3) Dissolve 1 mg of MLT@Hb-MG1 in water to prepare a 1 mg / mL aqueous solution to obtain an aqueous phase;
[0058] (4) 800 μL of the oil phase was added dropwise to 5 mL of the water phase to obtain colostrum, and the colostrum was passed through a liposome extruder to adjust the particle size of MLT@Hb-MLR, and after dialysis and ultrafiltration, hemoglobin nanoparticles MLT@Hb-MLR were obtained. The structural schematic diagram of hemoglobin nanoparticles MLT@Hb-MLR is shown in Figure 1 .
[0059] Experimental Results
[0060] 1. UV-visible absorption spectrum test: UV-2600i UV spectrophotometer was used to measure the UV-visible absorption spectra of Hb NPs, RVG-29, MLT@Hb, DSPE-TK-PEG2000-Mal, MLT, DSPE-TK-PEG2000-RVG29, and rice grain materials. The results are shown in Figure 2 , indicating that MLT@Hb and DSPE-TK-PEG2000-RVG29 were successfully synthesized
[0061] 2. Infrared spectrum test: Use Fourier transform micro-infrared spectrometer (model: American ThermoScientific Nicolet iN10) to perform infrared spectrum test. The results are shown in Figure 3 , indicating that MLT@Hb and MLT@Hb-MLR nanoparticles were successfully synthesized.
[0062] 3. Particle size and potential test;
[0063] MLT@Hb, MLT@Hb-MG1, and MLT@Hb-MLR were diluted with ultrapure water (10 times), and then the particle size and potential were tested using the particle size and potential mode of the Zetasizer Nano ZS90 particle size analyzer. The results are shown in Figure 4 As shown, the particle size results show that the synthesized nanoparticles are all less than 100 nm and have good stability.
[0064] 4. Stability test;
[0065] In order to evaluate the stability of MLT@Hb-MLR, MLT@Hb-MLR and PBS solution were mixed in a ratio of 1:1 and then left to stand at room temperature for 0, 12, 24, 36, and 48 h. The average particle size of MLT@Hb-MLR nanomaterial particles at different times was measured using a Zetasizer Nano ZS90 particle size analyzer to evaluate the particle size stability of the samples. Figure 5 As shown in the figure, with the extension of the standing time, the average particle size of the nanoparticles decreases to a certain extent, but tends to be stable, which proves that the MLT@Hb-MLR nanomaterial particles have good stability.
[0066] 5. Transmission electron microscope (TEM, model: ThermoScientific Talos L120C):
[0067] 70 μL of Hb, MLT@Hb, and MLT@Hb-MLR diluted 10 times with ultrapure water were dropped on a special copper grid. After 3 minutes, the excess liquid was removed with filter paper, and then 70 μL of 2% uranyl acetate was added for negative staining. After 3 minutes, the excess liquid was removed with filter paper, and the cells were dried naturally. The morphologies of Hb, MLT@Hb, and MLT@Hb-MLR were observed with a TEM electron microscope. Figure 7 TEM results show that the synthesized nanoparticles are spherical with rough surfaces and a size less than 100 nm, which is consistent with the particle size results.
[0068] 6. Responsiveness test:
[0069] (1) Particle size and PDI
[0070] In order to evaluate the responsiveness of MLT@Hb-MLR, MLT@Hb-MLR and PBS solution were mixed in a volume ratio of 1:1, and then allowed to stand at room temperature for 1, 2, 4, 6, and 12 h, respectively. The average particle size and PDI of the MLT@Hb-MLR nanomaterial particles at different times were measured using a Zetasizer Nano ZS90 particle size analyzer, and the samples were photographed by TEM electron microscope at 24 h. Figure 8 As shown, with the extension of the standing time, the average particle size of the nanoparticles gradually decreased, and TEM electron microscopy showed that the nanoparticles were significantly decomposed. The synthesized responsive nanoparticles had a good response to ROS.
[0071] (2) In order to evaluate the ROS-responsive release performance of MLT@Hb-MLR, MLT@Hb-MLR was placed in a dialysis bag and then placed in PBS and PBS solutions containing 0.1, 1, and 10 mM H2O2, respectively, and shaken in a constant temperature shaker at 37 °C. Then, 1 mL of the solution was taken for 2, 4, 6, 8, 10, 12, and 24 h, and then 1 mL of the corresponding solution was added. The concentration of MLT@Hb-MLR at different times was tested by HPLC, and the release amount at different time points was calculated by the cumulative method, as shown in Figure 2. Fig. 9 ,With the increase of H2O2 concentration, the release amount gradually increased, indicating that ,the nanoparticles were successfully synthesized and had good ROS responsiveness.
Claims
1. A method for preparing ROS-responsive liposome nanoparticles, characterized in that: The following steps are involved: MLT@Hb nanoparticles were synthesized and then connected to MG1 via 4-(N-maleimidomethyl)cyclohexane-1-carboxylic acid succinimidyl ester (SMCC) to form MLT@Hb-MG1; DSPE-TK-PEG2000-Mal and RVG29 were mixed to form DSPE-TK-PEG2000-RVG29, and then DSPE-TK-PEG2000-RVG29, MLT@Hb-MG1, soybean phosphatidylcholine and cholesterol were mixed to form liposome nanoparticles.
2. The method for preparing ROS-responsive liposome nanoparticles according to claim 1, characterized in that: The specific steps include: S1: Synthesis of MLT@Hb nanoparticles: Hb and melatonin solution were mixed in a buffer solution and stirred at room temperature for 3-6 h. After completion, the excess nanoparticles were removed by dialysis and filtered to obtain MLT@Hb nanoparticles. S2: Synthesis of MLT@Hb-MG1: MLT@Hb nanoparticles and SMCC were mixed, pH was adjusted, stirred at room temperature for 45-60 min, MG1 targeting peptide was added, reacted for 10-15 h, and purified by dialysis to obtain MLT@Hb-MG1; S3: Synthesis of DSPE-TK-PEG2000-RVG29: DSPE-TK-PEG2000-Mal and RVG29 cell targeting peptide were dissolved in PBS, stirred at room temperature overnight, and dialyzed to remove free RVG29 cell targeting peptide to obtain DSPE-TK-PEG2000-RVG29; S4: MLT@Hb-MLR synthesis: (1) weighing hydrogenated soybean phosphatidylcholine, cholesterol and DSPE-TK-PEG2000-RVG29, dissolving them in a solvent and heating to dissolve them to obtain a mixed solution; (2) adding the mixed solution to a solvent to obtain an oil phase; (3) dissolving MLT@Hb-MG1 in water to prepare an aqueous solution to obtain an aqueous phase; (4) The oil phase is added dropwise into the aqueous phase to obtain colostrum, and the particle size of MLT@Hb-MLR is regulated by a liposome extruder. After dialysis and ultrafiltration, ROS-responsive liposome nanoparticles MLT@Hb-MLR are obtained.
3. The method for preparing ROS-responsive liposome nanoparticles according to claim 2, characterized in that: The raw materials prepared in step S1 also include one or more of dopamine hydrochloride, BSA, HAS, and pigment protein.
4. The method for preparing ROS-responsive liposome nanoparticles according to claim 2, characterized in that: The mass ratio of Hb to melatonin in the melatonin solution is (3-7):
2.
5. The method for preparing ROS-responsive liposome nanoparticles according to claim 2, characterized in that: The molar ratio of MLT@Hb nanoparticles to SMCC in S2 is (1-3):
1.
6. The method for preparing ROS-responsive liposome nanoparticles according to claim 2, characterized in that: The molar ratio of the SMCC and MG1 targeting peptide is (1-3):
1.
7. The method for preparing ROS-responsive liposome nanoparticles according to claim 2, characterized in that: The mass ratio of DSPE-TK-PEG2000-Mal and RVG29 cell targeting peptide in the S3 is (1-3):
1.
8. The method for preparing liposome nanoparticles according to claim 2, characterized in that: The mass ratio of hydrogenated soybean phosphatidylcholine, cholesterol and DSPE-TK-PEG2000-RVG29 in S4 is (2-4):(1-2):
1.
9. Liposome nanoparticles prepared according to the method for preparing ROS-responsive liposome nanoparticles according to any one of claims 1 to 8.
10. A use of the ROS-responsive liposome nanoparticles according to claim 9, characterized in that: Used in preparing drugs for treating stroke.
